Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306
Matthias F. Froelich(Heidelberg University), Julian Walter Holch(Ludwig-Maximilians-Universität München), Volker Heinemann(LMU Klinikum), Wieland H. Sommer, Dominik Nörenberg(Heidelberg University), Elina Petersen(Universität Hamburg), Dominik Paul Modest(Berliner Hochschule für Technik), Felix O. Hofmann(German Cancer Research Center), Nina Hesse(Ludwig-Maximilians-Universität München), Alena Britta Gesenhues(LMU Klinikum), Sebastian Stintzing(Humboldt-Universität zu Berlin)
Cited by 9
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
|JAMA Oncology|2016|722
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
|European Journal of Cancer|2016|533